Owkin S News Today

And here we have the information that you receive after the ai has looked at the data? exactly. so here, for example, i can see that the ai risk is low. its a low—risk patient. some cancer experts see real promise in al tools like owkin�*s, but there are still challenges. its really exciting work, - and its showing where the future lies for pathology. while it might not be absolutely. there yet for clinical deployment, i think its a really important first step and something - that we should ...

Made its assessment of the risk. in this case, its low, but when its at a more moderate level, the dilemma really exists. sometimes, there is a grey zone and some cases are borderline, so maybe not completely good prognosis, maybe completely bad. and in this grey zone, we need other tools to decide for the prognosis of the patient. and here, we have the information that you receive after the als looked at the data. exactly. so here, for example, i can see that the ai risk is low — its a low—...

So here, for example, i can see that the ai risk is low — its a low—risk patient. some cancer experts see real promise in al tools like owkins, but there are still challenges. its really exciting - work and its showing where the future lies for pathology. while it might not be absolutely. there yet for clinical deployment, i think its a really important first step, and something. that we should be encouraged by. the real benefit to patients of these is patient safety . in the first instance ...